The 5th Annual Psychedelic Therapeutics and Drug Development Conference

Start: Monday, May 19, 2025 8:00AM
End: Tuesday, May 20, 2025 3:30PM

Following the success of the 4th Annual Psychedelic Therapeutics and Drug Development Conference in 2024, we're thrilled to be hosting the 5th Annual event on May 19-20, 2025 in San Diego, CA USA. This event has been organized to bring together the world’s leading researchers and leaders in academia, industry, the non-profit sector and government to discuss the challenges and opportunities facing those engaged in the research and development of psychedelics for various health conditions with considerable unmet need. This event will highlight the progress being made towards regulatory approval of a variety of psychedelics with the potential to treat various conditions, including inflammatory/autoimmune disorders, brain injury, pain, PTSD, anxiety, ADHD, headaches, depression, and opioid use disorder.

Our speakers and panelists will be covering important topics such as Clinical Trial Design, Intellectual Property, Regulatory Guidance, Psychedelic Drug Delivery, Commercialization, Legal Issues, Emerging Preclinical Science, and New Clinical Data among other topics. This event has been designed and curated for the benefit of key stakeholders in this burgeoning area and will provide practical guidance, discussion and networking.

Tickets: https://go.evvnt.com/2938288-2?pid=3698

Speakers: CHAIR: Peter Hendricks, Ph.D. Professor, Department of Psychiatry University of Alabama Birmingham, Matthew Baggott, Ph.D. Co-founder & Chief Executive Officer Tactogen, Judy Blumstock Chief Executive Officer, Founder, Director Diamond Therapeutics, Javier Muniz, MD (Formerly) Associate Director for Therapeutic Review/VP Research & Development Strategy US FDA/MindMed, Jon Kostas Chief Executive Officer/President & Chief Executive Officer Apollo Pact/Association for Prescription Psychedelics, Shlomi Raz Partner Negev Labs, Adam Halberstadt, Ph.D. Assistant Professor, Psychopharmacology Director, Center for Psychedelic Research University of California San Diego, Theresa Lii, MD, MS Instructor & Pain Medicine Attending, Department of Anesthesiology, Perioperative and Pain Medicine Stanford University School of Medicine, Mark M. Rasenick, Ph.D. Distinguished Professor of Physiology & Biophysics and Psychiatry/Chief Scientific Officer University of Illinois College of Medicine/Pax Neuroscience, Graham Pechenik, JD Founder, Patent Attorney Calyx Law, Adrienne Jo, Ph.D. Senior Associate Palo Santo, Mark Theeuwes Chief Operating Officer Reunion Neuroscience, Sean Goldy, Ph.D. Postdoctoral Fellow Johns Hopkins University School of Medicine, Gretchen Shaub, MPP Founding Partner & Strategic Advisor/Formerly Director, State & Government Affairs & Advocacy Interstice Strategies/Lykos Therapeutics, Sam Banister, Ph.D. Chief Scientific Officer, Co-founder Xylo Bio, Omar Ahmed, Ph.D. Associate Professor University of Michigan, Dillan DiNardo Co-founder and Chief Executive Officer Mindstate Design Labs, Richard Kropp Managing Partner ZINQ Capital, Maha Mian, Ph.D. Assistant Professor, Department of Psychology/Research Associate, Department of Psychiatry & Behavioral Sciences Suffolk University/UC San Francisco, Elliot Marseille, DrPH, MPP Director/Principal Collaborative for the Economics of Psychedelics (UCB/UCSF)/Health Strategies International, David Bender, MD Washington University in St. Louis, Bob Discordia, Ph.D. Co-Founder & Chief Executive Officer Equulus Therapeutics, William Smith, MD Founder & Chief Executive Officer AMR (Alliance for Multispecialty Research), Sara Shoar, MPH Incoming Ph.D. Candidate University of Southern California, Keck Medicine

Prices:
Industry: USD 1595.00
Government/Academic/Non-Profit/Clinician: USD 775.00
Graduate Students/Fellows: USD 575.00
Undergraduate Students: USD 450.00